The importance of epigenetics in the development of chronic obstructive pulmonary disease

Respirology

Volumn 16, Issue 7, 2011, Pages 1056-1063

  Sakao, Seiichiro ^a   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

acetylation; chronic obstructive pulmonary disease; epigenetics; genetics; histone deacetylase

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; CASEIN KINASE II; CORTICOSTEROID; CURCUMIN; EPOXIDE HYDROLASE; GELATINASE B; GLUCOCORTICOID RECEPTOR; GLUTATHIONE TRANSFERASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MICROSOMAL EPOXIDE HYDROLASE; MUCIN 2; MUCIN 5B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; THEOPHYLLINE; TOBACCO SMOKE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANGIOGENESIS; APOPTOSIS; ASTHMA; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DEACETYLATION; DISEASE COURSE; DNA METHYLATION; DNA MODIFICATION; DRUG SENSITIVITY; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HISTONE ACETYLATION; HUMAN; JAPANESE; LOW DRUG DOSE; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DNA INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID INSENSITIVITY;

DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TRANSCRIPTIONAL ACTIVATION;

EID: 80053302944     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02032.x     Document Type: Review

References (97)

1. Buist AS, McBurnie MA, Vollmer WM, et al,. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population based prevalence study. Lancet 2007; 370: 741-0.
2. Halbert RJ, Natoli JL, Gano A, et al,. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28: 523-32. (Pubitemid 44794666)
3. Mannino DM, Buist AS,. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-73. (Pubitemid 47321908)
4. Tager IB, Rosner B, Tishler PV, et al,. Household aggregation of pulmonary function and chronic bronchitis. Am. Rev. Respir. Dis. 1976; 114: 485-92.
5. Kauffmann F, Tager IB, Muñoz A, et al,. Familial factors related to lung function in children aged 6-10 years. Results from the PAARC epidemiologic study. Am. J. Epidemiol. 1989; 129: 1289-99. (Pubitemid 19148469)
6. Redline S, Tishler PV, Lewitter FI, et al,. Assessment of genetic and nongenetic influences on pulmonary function: a twin study. Am. Rev. Respir. Dis. 1987; 135: 217-22. (Pubitemid 17223916)
7. Givelber RJ, Couropmitree NN, Gottlieb DJ, et al,. Segregation analysis of pulmonary function among families in the Framingham Study. Am. J. Respir. Crit. Care Med. 1989; 157: 1445-51.
8. Smolonska J, Wijmenga C, Postma DS, et al,. Meta-analyses on suspected chronic obstructive pulmonary disease genes. Am. J. Respir. Crit. Care Med. 2009; 180: 618-31.
9. Silverman EK, Vestbo J, Agusti A, et al,. Opportunities and challenges in the genetics of COPD 2010: an international COPD genetics conference report. COPD 2011; 8: 121-35.
10. Sakao S, Tatsumi K, Igari H, et al,. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 420-2. (Pubitemid 32158522)
11. Sakao S, Tatsumi K, Igari H, et al,. Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high resolution CT in patients with COPD. Chest 2002; 122: 416-20. (Pubitemid 35002115)
12. Hersh CP, Demeo DL, Lange C, et al,. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am. J. Respir. Cell. Mol. Biol. 2005; 33: 71-8. (Pubitemid 40961016)
13. Sandford AJ, Chagani T, Weir TD, et al,. Susceptibility genes for rapid decline of lung function in the lung health study. Am. J. Respir. Crit. Care Med. 2001; 163: 469-73. (Pubitemid 32158530)
14. Seifart C, Dempfle A, Plagens A, et al,. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 2005; 65: 93-100. (Pubitemid 40179668)
15. Feinberg AP, Tycko B,. The history of cancer epigenetics. Nat. Rev. Cancer 2004; 4: 143-53. (Pubitemid 38198742)
16. Gal-Yam EN, Saito Y, Egger G, et al,. Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med. 2007; 59: 267-80.
17. McLachlan JA, Burow M, Chiang TC, et al,. Gene imprinting in developmental toxicology: a possible interface between physiology and pathology. Toxicol. Lett. 2001; 120: 161-4. (Pubitemid 32375082)
18. Bibikova M, Chudin E, Wu B, et al,. Human embryonic stem cells have a unique epigenetic signature. Genome Res. 2006; 16: 1075-83. (Pubitemid 44320394)
19. Amos-Landgraf JM, Cottle A, Plenge RM, et al,. X chromosome-inactivation patterns of 1005 phenotypically unaffected females. Am. J. Hum. Genet. 2006; 79: 493-9. (Pubitemid 44384258)
20. Fraga MF, Ballestar E, Paz MF, et al,. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. USA 2005; 102: 10604-9. (Pubitemid 41061601)
21. Seligson DB, Horvath S, Shi T, et al,. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-6. (Pubitemid 40943093)
22. Fischer A, Sananbenesi F, Wang X, et al,. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007; 447: 178-82. (Pubitemid 46763080)
23. Miller CA, Sweatt JD,. Covalent modification of DNA regulates memory formation. Neuron 2007; 53: 857-69. (Pubitemid 46367557)
24. Schwartz DA,. Epigenetics and environmental lung disease. Proc. Am. Thorac. Soc. 2010; 7: 123-5.
25. Coward WR, Watts K, Feghali-Bostwick CA, et al,. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol. 2009; 29: 4325-39.
26. Adcock IM, Tsaprouni L, Bhavsar P, et al,. Epigenetic regulation of airway inflammation. Curr. Opin. Immunol. 2007; 19: 694-700. (Pubitemid 350236802)
27. Anway MD, Cupp AS, Uzumcu M, et al,. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005; 308: 1466-69. (Pubitemid 40791300)
28. Seifart C, Plagens A,. Genetics of chronic obstructive pulmonary disease. Int. J. COPD 2007; 2: 541-50.
29. Minematsu N, Nakamura H, Tateno H, et al,. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem. Biophys. Res. Commun. 2001; 289: 116-9. (Pubitemid 33108801)
30. Joos L, He JQ, Shepherdson MB, et al,. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum. Mol. Genet. 2002; 11: 569-76. (Pubitemid 34257493)
31. Zhou M, Huang SG, Wan HY, et al,. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south. China Chin. Med. J. 2004; 117: 1481-4. (Pubitemid 39530225)
32. Poller W, Meisen C, Olek K,. DNA polymorphisms of the alpha 1-antitrypsin gene region in patients with chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 1990; 20: 1-7. (Pubitemid 20056266)
33. Benetazzo MG, Gilè LS, Bombieri C, et al,. Alpha 1-antitrypsin TAQ I polymorphism and alpha 1-antichymotrypsin mutations in patients with obstructive pulmonary disease. Respir. Med. 1999; 93: 648-54. (Pubitemid 29476255)
34. Poller W, Faber JP, Weidinger S, et al,. A leucine-to-proline substitution causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 1993; 17: 740-3. (Pubitemid 23282831)
35. Baranova H, Perriot J, Albuisson E, et al,. Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis. Hum. Genet. 1997; 99: 822-6. (Pubitemid 27243765)
36. Yim JJ, Park GY, Lee CT, et al,. Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1. Thorax 2000; 55: 121-5. (Pubitemid 30245951)
37. Harrison DJ, Cantlay AM, Rae F, et al,. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum. Exp. Toxicol. 1997; 16: 356-60. (Pubitemid 27371243)
38. Horne SL, Cockcroft DW, Dosman JA,. Possible protective effect against chronic obstructive airways disease by the GC 2 allele. Hum. Hered. 1990; 40: 173-6. (Pubitemid 20171005)
39. Hu G, Shi Z, Hu J, et al,. Association between polymorphisms of microsomal epoxide hydrolase and COPD: results from meta-analyses. Respirology 2008; 13: 837-50.
40. He JQ, Ruan J, Connett JE, et al,. Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am. J. Respir. Crit. Care Med. 2002; 166: 323-8. (Pubitemid 34864420)
41. Hassett C, Aicher L, Sidhu JS, et al,. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet. 1994; 3: 421-8. (Pubitemid 24083901)
42. Pillai SG, Ge D, Zhu G, et al,. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009; 5: e1000421.
43. Li B, Carey M, Workman JL,. The role of chromatin during transcription. Cell 2007; 128: 707-19. (Pubitemid 46273570)
44. Bowman RV, Wright CM, Davidson MR, et al,. Epigenomic targets for the treatment of respiratory disease. Expert. Opin. Ther. Targets 2009; 13: 625-40.
45. Barnes PJ,. Role of HDAC2 in the Pathophysiology of COPD. Annu. Rev. Physiol. 2009; 71: 451-64.
46. Ito K, Ito M, Elliott WM, et al,. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 2005; 352: 1967-76. (Pubitemid 40638367)
47. Ito K, Lim S, Caramori G, et al,. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001; 15: 1110-2.
48. Szulakowski P, Crowther AJ, Jimenez LA, et al,. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 41-50. (Pubitemid 43955243)
49. Mroz RM, Noparlik J, Chyczewska E, et al,. Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. J. Physiol. Pharmacol. 2007; 58: 453-60. (Pubitemid 351346694)
50. Mroz RM, Holownia A, Chyczewska E, et al,. Chronic obstructive pulmonary disease: an update on nuclear signaling related to inflammation and anti-inflammatory treatment. J. Physiol. Pharmacol. 2008; 59: 35-42.
51. Rajendrasozhan S, Yao H, Rahman I,. Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. COPD 2009; 6: 291-7.
52. Yeung F, Hoberg JE, Ramsey CS, et al,. Modulation of NFkappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23: 2369-80. (Pubitemid 38954844)
53. Rajendrasozhan S, Yang SR, Edirisinghe I, et al,. Deacetylases and NF-κB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid. Redox Signal. 2008; 10: 799-811. (Pubitemid 351225898)
54. Rajendrasozhan S, Yang SR, Kinnula VL, et al,. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 861-70. (Pubitemid 351600664)
55. Thai P, Loukoianov A, Wachi S, et al,. Regulation of airway mucin gene expression. Annu. Rev. Physiol. 2008; 70: 405-29. (Pubitemid 351738186)
56. Vincent A, Perrais M, Desseyn JL, et al,. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007; 26: 6566-76. (Pubitemid 47530602)
57. Barnes PJ, Adcock IM, Ito K,. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25: 552-63. (Pubitemid 40331188)
58. Rahman I, Marwick J, Kirkham P,. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-κB and pro-inflammatory gene expression. Biochem. Pharmacol. 2004; 68: 1255-67. (Pubitemid 39094292)
59. Rahman I,. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell. Biochem. Biophys. 2005; 43: 167-88. (Pubitemid 41095282)
60. Rahman I, Adcock IM,. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 2006; 28: 219-42. (Pubitemid 44914279)
61. Moodie FM, Marwick JA, Anderson CS, et al,. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-κB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J. 2004; 18: 1897-9. (Pubitemid 39602276)
62. Yang SR, Chida AS, Bauter MR, et al,. Cigarette smoke induces proinflammatory cytokine release by activation of NF-κB and posttranslational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 291: L46-57.
63. Barnes PJ,. Transcription factors in airway diseases. Lab. Invest. 2006; 86: 867-72. (Pubitemid 44268162)
64. Barnes PJ, Ito K, Adcock IM,. A mechanism of corticosteroid resistance in COPD: inactivation of histone deacetylase. Lancet 2004; 363: 731-3. (Pubitemid 38296564)
65. McGee SL, Hargreaves M,. Histone modifications and skeletal muscle metabolic gene expression. Clin. Exp. Pharmacol. Physiol. 2010; 37: 392-6.
66. Tsai SC, Seto E,. Regulation of histone deacetylase 2 by protein kinase CK2. J. Biol. Chem. 2002; 277: 31826-33. (Pubitemid 34968989)
67. Adenuga D, Yao H, March TH, et al,. Histone deacetylase 2 is phosphorylated, ubiquitinated and degraded by cigarette smoke. Am. J. Respir. Cell. Mol. Biol. 2009; 40: 464-73.
68. Galasinski SC, Resing KA, Goodrich JA, et al,. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J. Biol. Chem. 2002; 277: 19618-26. (Pubitemid 34967475)
69. Adenuga D, Rahman I,. Protein kinase CK2-mediated phosphorylation of HDAC2 regulates co-repressor formation, deacetylase activity and acetylation of HDAC2 by cigarette smoke and aldehydes. Arch. Biochem. Biophys. 2010; 498: 62-73.
70. Marwick JA, Caramori G, Stevenson CS, et al,. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am. J. Respir. Crit. Care Med. 2009; 179: 542-8.
71. Yang SR, Wright J, Bauter M, et al,. Sirtuin regulates cigarette smokeinduced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 292: L567-576.
72. McBurney MW, Yang X, Jardine K, et al,. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol. Cell. Biol. 2003; 23: 38-54. (Pubitemid 36008499)
73. Barnes PJ,. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2009; 6: 693-6.
74. Barnes PJ,. How corticosteroids control inflammation. Br. J. Pharmacol. 2006; 148: 245-54.
75. Ito K, Barnes PJ, Adcock IM,. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1b-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 2000; 20: 6891-903.
76. Ito K, Yamamura S, Essilfie-Quaye S, et al,. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 2006; 203: 7-13. (Pubitemid 43139638)
77. Adcock IM, Ito K, Barnes PJ,. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2005; 2: 445-55. (Pubitemid 43879443)
78. Meja KK, Rajendrasozhan S, Adenuga D, et al,. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am. J. Respir. Cell. Mol. Biol. 2008; 39: 312-23.
79. Adcock IM, Barnes PJ,. Molecular mechanisms of corticosteroid resistance. Chest 2008; 134: 394-401.
80. Haberg SE, London SJD, Stigum H, et al,. Folic acid supplements in pregnancy and early childhood respiratory health. Arch. Dis. Child. 2009; 94: 180-4.
81. Magnusson L, Olesen A, Wennborg H, et al,. Wheezing, asthma, hayfever, and atopic eczema in childhood following exposure to tobacco smoke in fetal life. Clin. Exp. Allergy 2005; 35: 1550-6.
82. Breton CV, Byun HM, Wenten M, et al,. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am. J. Respir. Crit. Care Med. 2009; 180: 462-7.
83. Ege MJ, Herzum I, Büchele G, et al,. Protection Against Allergy Study in Rural Environments (PASTURE) Study group. Prenatal exposure to a farm environment modifies atopic sensitization at birth. J. Allergy Clin. Immunol. 2008; 122: 407-12.
84. Ito K, Lim S, Caramori G, et al,. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA 2002; 99: 8921-6. (Pubitemid 34693659)
85. Ford PA, Durham AL, Russell RE, et al,. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010; 137: 1338-44.
86. Milne JC, Lambert PD, Schenk S, et al,. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6. (Pubitemid 350207685)
87. Sasaki T, Maier B, Koclega KD, et al,. Phosphorylation regulates SIRT1 function. PLoS ONE 2008; 3: e4020.
88. Caito S, Cook S, Yang SR, et al,. Redox regulation and post-translational modification of sirtuin in response to cigarette smoke in lung epithelial cells. Am. J. Respir. Crit. Care Med. 2008; 177: A348.
89. Caito S, Cook S, Yang SR, et al,. Sirtuin 1, an oxidant sensitive deacetylase, is posttranslationally modified and degraded by proteasome in reponse to cigarette smoke in lung epithelial cells. FASEB J. 2008; 22: 747-1.
90. Nicodeme E, Jeffrey KL, Schaefer U, et al,. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-23.
91. Filippakopoulos P, Qi J, Picaud S, et al,. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73.
92. Fujiwara K, Fujimoto N, Tabata M, et al,. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin. Cancer Res. 2005; 11: 1219-25. (Pubitemid 40175774)
93. Machida EO, Brock MV, Hooker CM, et al,. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer. Res. 2006; 66: 6210-8.
94. Mannino DM, Buist AS, Petty TL, et al,. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-93. (Pubitemid 36560940)
95. American Association for Cancer Research Human Epigenome Task Force and The European Union NoE, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature 2008; 454: 711-15.
96. Pottelberge GR, Mestdagh P, Bracke KR, et al,. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011; 183: 898-906.
97. Szulwach KE, Li X, Smrt RD, et al,. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J. Cell. Biol. 2010; 189: 127-41.